CIK 0001213037
- Non-accelerated filer
- Smaller reporting company
Cardiff Oncology, Inc.
Sign in to watch- Ticker
- CRDF
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 272004382
- Phone
- +1 858-952-7570
- Business address
- 11055 FLINTKOTE AVENUE, SAN DIEGO, CA, 92121
- Former names
- Trovagene, Inc., TrovaGene Inc., XENOMICS INC, USED KAR PARTS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 65 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-04-16 | Armitage James O Director | Grant or award · Stock Options | +11,916 | 11,916 | ||
| 2020-04-16 | White Lale Director | Grant or award · Stock Options | +11,916 | 11,916 | ||
| 2020-01-03 | Erlander Mark Chief Scientific Officer | Shares withheld for taxes | −116 | 6,376 | ||
| 2020-01-03 | Erlander Mark Chief Scientific Officer | Shares withheld for taxes | −552 | 6,231 | ||
| 2020-01-02 | Erlander Mark Chief Scientific Officer | Exercise or conversion | +261 | 6,492 | ||
| 2020-01-02 | Erlander Mark Chief Scientific Officer | Exercise or conversion · Restricted Stock Units | −261 | 260 | ||
| 2020-01-01 | Erlander Mark Chief Scientific Officer | Exercise or conversion | +1,250 | 6,783 | ||
| 2020-01-01 | Erlander Mark Chief Scientific Officer | Exercise or conversion · Restricted Stock Units | −1,250 | 521 | ||
| 2019-10-01 | Erlander Mark Chief Scientific Officer | Exercise or conversion | +1,250 | 5,999 | ||
| 2019-10-01 | Erlander Mark Chief Scientific Officer | Shares withheld for taxes | −466 | 5,533 | ||
| 2019-10-01 | Erlander Mark Chief Scientific Officer | Exercise or conversion · Restricted Stock Units | −1,250 | 1,771 | ||
| 2019-07-01 | Erlander Mark Chief Scientific Officer | Exercise or conversion | +1,250 | 5,210 | ||
| 2019-07-01 | Erlander Mark Chief Scientific Officer | Shares withheld for taxes | −461 | 4,749 | ||
| 2019-07-01 | Erlander Mark Chief Scientific Officer | Exercise or conversion · Restricted Stock Units | −1,250 | 3,021 | ||
| 2019-06-20 | JACOB GARY S Director | Grant or award · Stock Options | +44,734 | 48,071 | ||
| 2019-06-20 | ADAMS THOMAS PHD Chief Executive Officer | Grant or award · Stock Options | +298,230 | 304,725 | ||
| 2019-06-20 | Markin Rodney S Director | Grant or award · Stock Options | +44,734 | 46,969 | ||
| 2019-06-20 | Erlander Mark Chief Scientific Officer | Grant or award · Stock Options | +134,203 | 158,959 | ||
| 2019-06-20 | Countouriotis Athena Director | Grant or award · Stock Options | +44,734 | 46,019 | ||
| 2019-06-20 | BRANCACCIO JOHN P Director | Grant or award · Stock Options | +44,734 | 47,806 |
Page 9 of 15 · 299 trades